NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Status:
Completed
Trial end date:
2006-04-25
Target enrollment:
Participant gender:
Summary
This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with
imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant
melanoma. The primary study objective was to determine the safety of NY-ESO-1
protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity
of treatment.
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig Institute for Cancer Research
Collaborators:
American Society of Clinical Oncology Cancer Research Institute (CRI)